menu
    • menu
    [{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"4","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"ANA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Nanoform","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","graph1":"Immunology","graph2":"Preclinical","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"South Rampart Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Acetaminophen Analog","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"OXL001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"HighTide Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quotient Sciences \/ HighTide Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Quotient Sciences \/ HighTide Therapeutics"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Emplicure"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat Mesylate","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"CRN04894","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Crinetics Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Crinetics Pharmaceuticals"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Evecxia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"South Rampart Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"YourChoice Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"YCT-529","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Medivir","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"YCT529","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"CTO1681","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Nafamostat HCl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Quotient Sciences

    Menu

    Quotient Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ensysce Advances Overdose Protection Platform in Clinical Development

                            Details : The collaboration aims to examine and evaluate the full commercial dose range of the PF614-MPAR drug product, the combination of PF614 with the trypsin inhibitor nafamostat, to treat chronic pain.

                            Brand Name : PF614-MPAR

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : South Rampart Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Completes Phase 1 Study and Expands Phase 2 Plans

                            Details : SRP 3D (diethylamide) is a first-in-class non-opioid analgesic activating pain signaling pathways in the midbrain's periaqueductal grey. It’s in phase 1 trials for acute pain.

                            Brand Name : SRP 3D

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 02, 2024

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : South Rampart Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : YCT529

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UK Launches First Trial of Hormone-Free Male Birth Control Pill

                            Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.

                            Brand Name : YCT-529

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : YCT529

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : YCT529

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : YourChoice Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quotient Sciences Supports YourChoice Therapeutics with Phase I Trial of Novel Hormone-Free Male Birth Control...

                            Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.

                            Brand Name : YCT-529

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 13, 2023

                            Lead Product(s) : YCT529

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : YourChoice Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Medivir

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quotient Sciences Supports Medivir with Updated Formulation of Fostrox

                            Details : MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Medivir

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : HSDB 4295,Carbidopa

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : Evecxia Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

                            Details : EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.

                            Brand Name : EVX-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2023

                            Lead Product(s) : HSDB 4295,Carbidopa

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : Evecxia Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : CRN04894

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Crinetics Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Quotient Sciences Supports Crinetics Pharmaceuticals with Fully Integrated Pediatric Development and Clinical ...

                            Details : Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and t...

                            Brand Name : CRN04894

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : CRN04894

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Crinetics Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study

                            Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...

                            Brand Name : PF614-MPAR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2023

                            Lead Product(s) : Oxycodone Prodrug,Nafamostat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ensysce Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Berberine Ursodeoxycholate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : HighTide Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

                            Details : HTD1801 (berberine ursodeoxycholate), is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

                            Brand Name : HTD1801

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : Berberine Ursodeoxycholate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : HighTide Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Quotient Sciences

                            United Kingdom
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Emplicure

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for E...

                            Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.

                            Brand Name : Empli03

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : Buprenorphine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Emplicure

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth